Compounds > ticlopidine
Page last updated: 2024-08-16

ticlopidine and mephenytoin

ticlopidine has been researched along with mephenytoin in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's9 (81.82)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Desta, Z; Flockhart, DA; Ko, JW; Soukhova, NV; Tracy, T1
Dunbar, D; Kaminsky, LS; Obach, RS; Zhang, QY1
Farid, NA; Hagihara, K; Ikeda, T; Ishizuka, T; Kazui, M; Kurihara, A; Nishiya, Y; Okazaki, O1
El Rouby, N; Goldstein, JA; Johnson, JA; Langaee, TY; Markowitz, JS; Wang, X; Zhu, HJ1
Calamia, JC; Chaudhry, AS; Fohner, A; Isoherranen, N; McDonald, M; Prasad, B; Rettie, AE; Schuetz, EG; Shirasaka, Y; Thornton, TA; Thummel, KE; Unadkat, JD; Wong, T1

Reviews

1 review(s) available for ticlopidine and mephenytoin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

10 other study(ies) available for ticlopidine and mephenytoin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity

2013
In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
    British journal of clinical pharmacology, 2000, Volume: 49, Issue:4

    Topics: Anticonvulsants; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Humans; Hypoglycemic Agents; In Vitro Techniques; Kinetics; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Muscle Relaxants, Central; Phenacetin; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tolbutamide

2000
Metabolic characterization of the major human small intestinal cytochrome p450s.
    Drug metabolism and disposition: the biological fate of chemicals, 2001, Volume: 29, Issue:3

    Topics: Adult; Aged; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Enterocytes; Female; Humans; Hydroxylation; Immunoblotting; Intestine, Small; Isoenzymes; Kinetics; Male; Mephenytoin; Microsomes; Middle Aged; Mixed Function Oxygenases; Regression Analysis; Sulfaphenazole; Testosterone; Ticlopidine

2001
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:1

    Topics: Antibodies; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Biotransformation; Cell Line; Cell Line, Tumor; Clopidogrel; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Glutathione; Humans; Ketoconazole; Kinetics; Mephenytoin; Microsomes; Microsomes, Liver; NADP; Omeprazole; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Sulfaphenazole; Theophylline; Ticlopidine

2010
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:8

    Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Catalysis; Chromatography, Liquid; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Kinetics; Mephenytoin; Omeprazole; Pharmacogenetics; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Tandem Mass Spectrometry; Ticlopidine

2014
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:4

    Topics: Activation, Metabolic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Gene Expression Regulation, Enzymologic; Gene Frequency; Genotype; Humans; Hydroxylation; Infant; Infant, Newborn; Kinetics; Linear Models; Liver; Male; Mephenytoin; Microsomes, Liver; Middle Aged; Multivariate Analysis; Oxidation-Reduction; Pharmacogenomic Variants; Phenotype; Substrate Specificity; Ticlopidine; Young Adult

2016